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Abstract: Mitochondria are intracellular organelles involved in a myriad of activities. To safeguard
their vital functions, mitochondrial quality control (MQC) systems are in place to support organelle
plasticity as well as physical and functional connections with other cellular compartments. In particular,
mitochondrial interactions with the endosomal compartment support the shuttle of ions and
metabolites across organelles, while those with lysosomes ensure the recycling of obsolete materials.
The extrusion of mitochondrial components via the generation and release of mitochondrial-derived
vesicles (MDVs) has recently been described. MDV trafficking is now included among MQC
pathways, possibly operating via mitochondrial–lysosomal contacts. Since mitochondrial dysfunction
is acknowledged as a hallmark of aging and a major pathogenic factor of multiple age-associated
conditions, the analysis of MDVs and, more generally, of extracellular vesicles (EVs) is recognized as
a valuable research tool. The dissection of EV trafficking may help unravel new pathophysiological
pathways of aging and diseases as well as novel biomarkers to be used in research and clinical settings.
Here, we discuss (1) MQC pathways with a focus on mitophagy and MDV generation; (2) changes
of MQC pathways during aging and their contribution to inflamm-aging and progeroid conditions;
and (3) the relevance of MQC failure to several disorders, including neurodegenerative conditions
(i.e., Parkinson’s disease, Alzheimer’s disease) and cardiovascular disease.
Keywords: biomarkers; exosomes; extracellular vesicles; geroprotective interventions; mitophagy;
mitochondrial damage; mitochondrial dynamics; mitochondrial-derived vesicles (MDVs);
mitochondrial-lysosomal axis; neurodegeneration
1. Introduction
Mitochondria are intracellular organelles that participate in nearly all biological processes by
ensuring energy supply, iron, and calcium buffering, signaling through reactive oxygen species, steroid
hormone and heme biosynthesis, and control of cell death/survival pathways [1,2]. Recent advances in
mitochondrial physiology have assigned a role for these organelles in pathways that are not canonically
linked with mitochondria, such as inflammation [3]. Given the multifaceted functions of mitochondria,
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it is not surprising that their (dys) function has attracted considerable interest in the setting of multiple
conditions (e.g., aging, cancer, neurodegeneration, cardiovascular disease, metabolic disorders) [4–8].
In order to guarantee efficient energy provision and proper integration of intracellular signaling,
mitochondria need to remain plastic and connected with other cellular compartments. Membrane
contact sites and tethering molecules are essential components of inter-organelle interactions [9–11].
Via these structures, mitochondria establish physical and functional interactions with the endosomal
compartment [12,13] and lysosomes [14,15]. While the first system supports ion and metabolite
shuttling across organelles [10,16], the interaction with lysosomes is in place to ensure the recycling of
obsolete materials [14,15].
The mitochondrial-lysosomal axis is recognized as the main actor in the deployment of
mitochondrial quality control (MQC). The latter involves a hierarchical network of pathways that
operate through the coordination of mitochondrial proteostasis, dynamics, biogenesis, and autophagy
to preserve organellar homeostasis [7].
The mitochondrial unfolded protein response (UPRmt) is a conserved stress-responsive system
essential for mitochondrial proteostasis [17]. UPRmt is composed mainly of the ATPases Associated
with diverse cellular Activities (AAA) p97 and the cofactor nuclear protein localization protein 4
(NPL4) [18]. Under stress conditions, several mitochondrial stress proteins, including chaperonin
10 and 60, mtDnaJ, ATP-dependent Clp protease proteolytic subunit (ClpP), and intermembrane
space AAA (i-AAA) protease supercomplex subunit (Yme1), are expressed to ensure mitochondrial
proteostasis [19]. Although the regulation of the UPRmt is not fully understood, activating transcription
factor 5 (ATF5) has been shown to orchestrate UPRmt in mammals [20].
Coordinated cycles of fusion and fission control mitochondrial shape, which is essential for
adequate energy provision and dilution of damage along the network [21]. Instead, mitochondrial
hyper-fission is in charge of segregating severely damaged or dysfunctional organelles [21] for their
eventual disposal via a specialized form of autophagy termed mitophagy [22]. Concomitantly,
mitochondrial replenishment via biogenesis maintains an adequate mitochondrial pool [23].
The establishment of mitochondrial-lysosomal contact sites has recently been included among
the mechanisms participating in MQC as an additional layer of quality check involving crosstalk
between the two organelles and culminating in the release of extracellular vesicles (EVs) [24]. Down
this alternative degradative route, mildly damaged mitochondrial components are processed and
disposed of within EVs of mitochondrial origin (mitochondrial-derived vesicles, MDVs) [25]. As such,
this mechanism contributes to organelle homeostasis before whole-sale mitochondrial degradation is
triggered [25].
Mitophagy dysregulation or impairment in the mitochondrial-lysosomal axis instigates the
intracellular accumulation of noxious materials (e.g., damaged mitochondria, misfolded proteins,
lipofuscin) [26]. In the long-term, the stalling of housekeeping systems further depresses cell recycling
processes, thereby impinging on cell homeostasis and tissue integrity [26].
Here, we discuss (1) canonical MQC pathways with a special focus on mitophagy and MDV
generation; (2) changes of MQC pathways during aging and their contribution to inflamm-aging
and progeroid conditions; and (3) the relevance of MQC failure to several disorders, including
neurodegenerative conditions such as Parkinson’s disease (PD), Alzheimer’s disease (AD), and
cardiovascular disease (CVD).
2. Mitophagy or Generation of Mitochondrial-Derived Vesicles: Easy Come Easy Go
The fine-tuning of MQC ensures mitochondrial plasticity, disposal, and replenishment to maintain
a well-functioning organelle network within the cell and to meet dynamic tissue energy demands [7].
Mitochondrial fission, under the control of the guanosine triphosphatase (GTPase) dynamin-related
protein 1 (DRP1), fission protein 1 (FIS1), and dynamin 2, regulates mitochondrial division and
biogenesis by modulating the rate of mitochondrial DNA (mtDNA) synthesis [27–32]. The tethering
and fusion of mitochondrial membranes are mediated by the outer membrane GTPases, mitofusin
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(MFN) 1 and MFN2, and the inner membrane GTPase, optic atrophy 1 (OPA1). Mitochondrial fusion
enables the exchange of proteins, mtDNA, and metabolites between networked organelles and allows
the dilution of mitochondrial damage [27]. Eventually, mitophagy is in place to remove irreversibly
damaged mitochondria and mitigate organelle dysfunction [33].
Mitophagy is a multi-step process beginning with the engulfment of damaged or unnecessary
mitochondria within a degradative structure named autophagosome. Autophagosomes fuse and deliver
their cargo to lysosomes and form an autolysosome wherein the engulfed material is degraded [22].
A sophisticated molecular machinery orchestrates the whole process, which may proceed via
serine/threonine-protein phosphatase and tensin homolog-induced kinase 1 (PINK1)/Parkin-dependent
and independent pathways [5]. PINK1/Parkin-dependent mitophagy is the best-studied pathway in
mammalian cells and is described here in more detail.
The proper disposal of dysfunctional mitochondria involves the coordinated activity of complex
molecular machinery. In healthy, polarized mitochondria, the translocase of the outer mitochondrial
membrane (TOM) and the translocase of inner mitochondrial membrane 23 (TIM23) support the import
of PINK1 within the organelle followed by its cleavage by the presenilin-associated rhomboid-like
(PARL) protein [34–36]. Conversely, the loss of mitochondrial membrane potential triggers the
accumulation and stabilization of PINK1 at the outer mitochondrial membrane (OMM) [35,37]. Here,
PINK1 is activated via autophosphorylation at specific serine residues [32], followed by the recruitment
of Parkin from the cytoplasm to the OMM [34,38–40] through the phosphorylation and ubiquitination at
serine 65 [41,42] (Figure 1). Once recruited, Parkin ubiquitinates proteins located at the OMM interface,
such as the voltage-dependent anion channel (VDAC), Ras homolog family member T1 (RHOT1),
and MFN1/2 that act as phosphoubiquitin substrates. Polyubiquitination enables the interaction of
mitochondria with mitophagy adapter proteins (i.e., nuclear dot protein 52 (NDP52) and optineurin
(OPTN)) and the microtubule-associated protein 1A/1B-light chain 3 (LC3) via a conserved amino
acid motif (WXXL) for delivery to autophagosomes [43,44] and sequestration within the isolation
membrane [45] (Figure 1). The completion of the degradative process is achieved after the accumulation
of the ubiquitin-binding adaptor protein p62/sequestosome-1 on depolarized mitochondria and its
binding to LC3 [45]. This event facilitates the delivery of mitochondria to autophagosomes to complete
their degradation [45].
Figure 1. Quality control of mitochondria through mitophagy. Severely depolarized mitochondria
are targeted to degradation by phosphatase and tensin homolog-induced kinase 1 (PINK1)-Parkin-
dependent and independent pathways. Through the mediation of the translocase of the outer
mitochondrial membrane (TOM) and the translocase of inner mitochondrial membrane 23 (TIM23),
PINK1 is imported into functional mitochondria and is degraded by presenilin-associated rhomboid-like
(PARL) protein. Upon mitochondrial depolarization, PINK1 accumulates at the outer mitochondrial
membrane (OMM), where it recruits Parkin to trigger mitophagy. A set of OMM proteins, including
FUN14 domain containing 1 (FUNDC1), autophagy and Beclin-1 regulator 1 (AMBRA1), B-cell
lymphoma 2 (BCL2)-interacting protein 3 like (BNIP3L), BNIP3, and disrupted-in-schizophrenia-1
(DISC1), assists the whole process by detecting damaged mitochondria and interacting with
microtubule-associated protein 1A/1B-light chain 3 (LC3). ROS, reactive oxygen species.
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The PINK1/Parkin-independent pathway of mitophagy relies on the activity of a set of
OMM-localized receptors, including B-cell lymphoma 2 (BCL2)-interacting protein 3 like (BNIP3L/NIX),
FUN14 domain-containing 1 (FUNDC1), BNIP3, autophagy, and Beclin-1 regulator 1 (AMBRA1),
BCL2-like 13 (BCL2L13), FKBP prolyl isomerase 8 (FKBP8), and disrupted-in-schizophrenia-1
(DISC1) [33] (Figure 1). These receptors detect damaged mitochondria by interacting with processed
LC3 at phagophores via a common LC3-interacting region (LIR) motif in their cytosolic N-terminal
domains. The description of these pathways does not fall within the scope of this review and can be
found elsewhere [33].
The mitophagy response triggered by complete mitochondrial depolarization has been thoroughly
characterized. Though, it remains unclear how the whole system makes coherent decisions on whether
to keep or purge mitochondria when they are only mildly damaged. Emerging evidence shows that,
at least in vitro, temporal integration of mitochondrial stress signals is mediated by the PINK1/Parkin
pathway according to the magnitude and duration of mitochondrial insults [46]. While PINK1 and
Parkin accumulate stably on completely depolarized mitochondria, only a transient stabilization of
PINK1 is observed in response to partial mitochondrial depolarization [46]. In this context, a slow
step-wise accumulation of Parkin occurs with consequent phospho-polyubiquitination and delayed
mitophagy [46]. Divergent rates of mitophagy degradation may also arise from the differential
phosphorylation of individual mitochondrial protein species by the activity of phosphatases and
kinases [47].
The Ras-related in Brain protein 7A (RAB7A), a ubiquitously expressed small GTPase belonging
to the RAB family, is a well-known regulator of mitophagy downstream of Parkin [48]. RAB7A shuttles
between an active, lysosomal-localized guanosine-5’-triphosphate (GTP)-bound state and an inactive,
cytosolic guanosine diphosphate (GDP)-bound state. This process is regulated by proteins with
Guanine nucleotide Exchange Factor (GEF)-function, that induce GDP dissociation and GTP binding,
and proteins with GTPase-Activating Protein (GAP)-function, that stimulate GTP hydrolysis [49].
Once recruited on the late endosomal-lysosomal membranes, RAB7A is activated by GEFs and interacts
with effector proteins through which it regulates multiple processes involved in MQC [49]. Via these
interactions, RAB7A regulates the maturation of early endosomes, the transport of intracellular
material from late endosomes to lysosomes, lysosomal biogenesis, and the clustering and fusion of late
endosomes and lysosomes in the perinuclear region of the cell [49]. Through its activities in endosomal
trafficking, RAB7A also participates in autophagy, mitophagy, secretion of EVs [49,50], and tethering
and untethering of mitochondrial-lysosomal contacts [15]. Hence, RAB7A is considered to be an
effector of mitophagy involved in autophagosome biogenesis [51]. To accomplish this task, RAB7A
cooperates with the Tre-2/Bub2/Cdc16 (TBC) domain family, member 15 and 17 (TBC1D15/TBC1D17)
and FIS1 [51]. In particular, the interaction of TBC1D15/17 with LC3 and FIS1 is essential to coordinate
RAB7A activity and guide the isolation of the pre-autophagosomal membrane that selectively engulfs
damaged mitochondria [51]. The silencing of RAB7A suppresses abnormal LC3 accumulation and
tubulation in TBC1D15–/– cells [51]. Thus, while constitutive RAB7A activity favors the expansion
of the LC3-positive isolation membrane, RAB7A inactivation may be required for the release of
LC3-bound membranes from microtubules [51,52]. This confers to RAB7A further roles besides that of
controlling the final step of the maturation of autophagosomes by their fusion with lysosomes [53,54].
This function seems to be mediated by the interaction of RAB7A with MFN2 during the maturation of
the autophagosomal membrane [55]. Thus, RAB7A may support both autophagosome formation and
maturation during mitophagy.
A recent study showed that RAB7A is involved in mitophagy also via its regulation by the
retromer complex [56]. The latter is a multi-subunit complex that orchestrates the retrograde transport
of materials from endosomes to the Trans-Golgi Network (TGN) or from endosomes to the plasma
membrane [57]. The complex includes vacuolar protein sorting (Vps) 26, Vps29, and Vps35 that
constitute a heterotrimeric cargo recognition subcomplex and sorting nexin (SNX) proteins that form
hetero/homo-dimeric subcomplex of retromer. The localization of the retromer at the endosomal
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membrane is enabled by the simultaneous interaction of Vps35 with active RAB7A-GTP and SNX3 [49].
RAB7A activity is controlled by TBC1D5, the retromer-associated RAB7-specific GAP, that interacts
with the subunit Vps29 of the retromer [58]. Due to this interaction, RAB7A localizes around damaged
mitochondria and promotes their removal through Parkin-mediated mitophagy [56]. If the retromer
is lost, hyperactivated RAB7A is sequestered on late endocytic membranes and cannot localize on
damaged mitochondria, eventually resulting in defects in the mitophagosome formation [56].
Post-translational modifications of RAB7A also play a critical role in mitophagosome formation.
RAB7A activity is regulated by the Src kinase through serine-threonine phosphorylation at serine 72
(S72) and phosphorylation of tyrosine 183 (Y183) [59]. Recently, Heo and colleagues [60] found that
RAB7A S72 is a target of tumor necrosis factor receptor-associated factor nuclear factor κB (NF-κB)
activator (TANK)-binding kinase 1 (TBK1), a kinase activated by the assembly of ubiquitin chains
on mitochondria and by mitochondria depolarization during mitophagy. A small fraction of RAB7A
is phosphorylated at S72 by TBK1 in a PINK1-Parkin dependent manner. RAB7A S72 interacts
with folliculin and the folliculin-interacting protein 1 (FLCN-FNIP1) complex to recruit damaged
mitochondria and promote Parkin-dependent mitophagy. Indeed, cells with mutations in RAB7A
phosphorylation sites exhibit defects in the recruitment of damaged mitochondria [60].
The identification of MQC members among the regulators of mitophagy led to hypothesize the
existence of inter-organelle functional connections, in particular mitochondrial–lysosomal contacts that
may represent a further level of MQC [16]. The observation that defects in either of the two organelles
induce impairments in the other further supports this interrelationship [61]. In particular, lysosomal
activity is impaired in the setting of deficient mitochondrial respiration and disruption of endolysosomal
trafficking [61]. Along similar lines, depletion or inhibition of apoptosis-inducing factor (AIF), OPA1,
or PINK1 in neurons impairs lysosomal activity, thereby inducing accrual of autophagic substrates [62].
Moreover, the restoration of lysosomal pH via the delivery of lysosome-targeted nanoparticles is able
to rescue mitophagy in pancreatic β cells exposed to high free fatty acid concentrations [63].
Altogether, these findings indicate that, under certain circumstances, mitochondrial dysfunction
develops as a consequence of lysosomal alkalization and that the restoration of lysosomal acidity
can reinstate an efficient MQC [63]. In the next paragraph, the possible fate of mildly damaged
mitochondria is discussed.
Generation and Release of Mitochondria-Derived Vesicles
Different from mitophagy, a shuttle system operating via the generation and release of EVs
is in place to dispose of mildly damaged mitochondria. This system operates independent of
mitochondrial depolarization, autophagy signaling, or mitochondrial fission [64]. Indeed, cells lacking
autophagy-related serine/threonine kinase gene (Atg) 5, Beclin-1, or RAB9, as well as silenced for DRP1,
are still able to generate MDVs [64].
Mitochondrial-enriched small EVs of ~100 nm in diameter [25] are likely delivered to lysosomes
for degradation of organellar components [64]. While proceeding in the absence of DRP1, MDV
biogenesis seems to require priming by PINK1 and Parkin [25]. Hence, MDV generation may belong
to degradative pathways via a system that complements mitophagy for MQC when this degradative
process is overwhelmed or compromised [65]. Although the molecular events underlying MDV
generation are still unclear, large double-membrane vesicles containing mitochondrial components
have been described, providing evidence of crosstalk between mitochondria and the endolysosomal
system [6,66]. A proposed mechanism for MDV generation involves the accrual of protein aggregates in
proximity to mitochondrial membranes under oxidative stress conditions [25]. This event, concomitant
with cardiolipin oxidation, would generate unconventional changes in mitochondrial membrane
structure, likely curvatures, that would compete with the function of organelle import channels [25].
The formation of mitochondrial membrane curvatures is thought to be followed by the accumulation
of PINK1 at the OMM, followed by ubiquitination and recruitment of Parkin [25]. The process would
J. Clin. Med. 2020, 9, 1440 6 of 22
eventually culminate in the formation of a vesicle which is then released through a process involving
unidentified proteins [25] (Figure 2).
Figure 2. Quality control of mitochondria through the generation and release of mitochondrial-derived
vesicles (MDVs). Mildly oxidized mitochondria are also targeted by phosphatase and tensin
homolog-induced kinase 1 (PINK1) and Parkin. This priming process, in conjunction with oxidized
cardiolipin (oxoCL)-driven membrane curvatures and other unknown proteins, assists in the generation
of MDVs. MDVs reach out to the endolysosomal system and form multivesicular bodies (MVBs) that
are extruded from cells as extracellular vesicles.
Down this road, mitochondrial-lysosomal membrane contact sites finely coordinate the
mitochondrial fate between mitophagy and MDV pathways. Indeed, while mitophagy represents
an “extreme” attempt of the cell to preserve homeostasis [22,67], MDV generation might dispose of
defective mitochondrial components and avoid the clearance of entire organelles [68,69] (Figure 2).
Notably, mitochondrial constituents displaced within MDVs (e.g., mtDNA) can activate several
inflammatory pathways through the interaction with (1) Toll-like receptors (TLRs), (2) Nod-like
receptor (NLR) family pyrin domain containing 3 (NLRP3) inflammasome, and (3) cytosolic cyclic
guanosine monophosphate–adenosine monophosphate (GMP–AMP) synthase (cGAS)—stimulator of
interferon genes (STING) DNA sensing system [70]. This response is mounted within the framework
of innate immunity and pertains to the “danger theory” of inflammation [71]. Indeed, noxious
material released from injured cells (i.e., damage-associated molecular patterns (DAMPs)) triggers
caspase–1 activation and the secretion of pro-inflammatory cytokines [72]. Of note, PINK and Parkin
suppress adaptive immunity responses by favoring the shuttling of oxidized cargo-enriched MDVs to
lysosomes for degradation [73]. This prevents the delivery of MDVs to endosomes where mitochondrial
components would be loaded on major histocompatibility complex (MHC) class I molecules for antigen
presentation [73].
The hypothesis of mitochondrial transfer within MDVs upon functional requests cannot be
disregarded. Some lines of evidence indicate that the transfer and uptake of functional mitochondria
within MDVs occurs in vitro and in vivo, especially in cells with mitochondrial defects [74–77].
This event rescues aerobic respiration and suggests a link between mitochondrial defects and endocytosis
of EVs [74–77]. However, whether and how this system contributes to the metabolic regulation of
distant cells warrants further investigation.
The persistence of chronic, sterile inflammation is a hallmark of aging [74]. This condition,
referred to as “inflamm-aging”, has been shown to contribute to the progression of aging itself and
the development of age-related conditions [78,79]. A link among MQC failure, MDV secretion, and
inflammation has been hypothesized in several contexts, including progeroid conditions such as human
immunodeficiency virus (HIV) infection, a model of accelerated and accentuated aging [80], multiorgan
failure [81], inflamm-aging [82], and neurodegeneration [6]. Although the pathophysiology of these
conditions is heterogeneous, the release of mitochondrial DAMPs may be a common pathogenic
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pathway. In this context, the scavenging of circulating mitochondrial DAMPs might represent an
unexplored therapeutic option for several disease conditions. Relevant pathways elicited upon MDV
release during aging are discussed in the next section.
3. Failing Mitochondrial Quality Control and Inflammation during Aging: Partners in Crime
An efficient MQC is pivotal for maintaining cell and organismal homeostasis. Indeed, declines
in MQC spanning from mitochondriogenesis to proteostasis via UPRmt have been described during
aging and age-associated conditions [23,83]. Alterations in the epigenetic regulation of genes involved
in MQC have recently been associated with mitochondrial dyshomeostasis, which may be relevant to
aging and chronic degenerative diseases [84]. Furthermore, methylation of specific mtDNA regions
may increase susceptibility to neurodegenerative diseases, including AD and PD [85]. Interestingly,
mitoepigenetics chromatin remodeling can activate the UPRmt signaling and promote longevity in
several eukaryotic species [86,87].
The tight relationship among age-related mitochondrial dysfunction, redox imbalance, and
inflammation is indirect evidence of MQC relevance for the cell [88]. Indeed, under specific
circumstances, redox-sensitive inflammatory pathways may be activated. This is the case of pathways
pertaining to mitochondrial calcium metabolism, iron handling, and reactive oxygen species (ROS)
production [89,90]. ROS bursts, in particular, act as major pro-inflammatory stimuli via the activation
of nuclear factor κB (NF-κB) [91]. The severity of the inflammatory response and the efficiency of
cellular quality control systems determine the cell’s fate. While an apoptotic cascade may be elicited
by moderate inflammatory stimuli and overwhelmed cellular repair systems, necrosis may ensue in
the setting of overt inflammation, mitochondrial dysfunction, and ROS-induced damage [92]. As a
consequence, cell components, including entire and fragmented mitochondria, may be extruded at
the systemic level in the form of cell-free molecules or within MDVs. Here, mtDNA and damaged
mitochondrial components may act as DAMPs and instigate inflammation by interacting with TLR,
NLRP, and cGAS–STING systems [93,94].
DAMPs can engage the TLR pathway that promotes neutrophils recruitment and the instigation
of an inflammatory response via NF-κB signaling [95]. Alternatively, mtDNA can induce inflammation
via NLRP3 inflammasome activation [96,97]. An NLRP3 inflammatory response has been observed in a
variety of conditions, including AD, cardiovascular disease, metabolic disorders, autoimmune diseases,
etc. (reviewed in [98]). NLRP3 operates through a set of cytosolic protein complexes that, upon
activation, engage caspase-1 and promote caspase-1-dependent cleavage and activation of interleukin
(IL) 1 and 18 [99]. The synergistic activity of redox-sensitive inflammatory and inflammasome-mediated
pathways concurs to reinforcing inflammation [100].
Albeit the molecular determinants linking inflammasome activation to inflamm-aging remain
to be clarified, the presence of bacterial-like motifs within the mtDNA that can be sensed by NLRs
are believed to play a major role [101]. Notably, a self-sustaining circle of mitochondrial dysfunction,
ROS bursts, and consequent mtDNA damage can be triggered by NLRP3 activators [97]. Among
these, oxidized mtDNA, once released, may serve as the ultimate NLRP3 ligand [97]. As such,
the activation of inflammasomes, including NLRP3, may be an upstream checkpoint of the innate
immune system during the deployment of inflamm-aging. The cGAS–STING DNA-sensing pathway
also contributes to sterile inflammation as part of the innate immune system [94]. In particular,
the binding of mtDNA to cGAS induces the recruitment of STING protein and the subsequent
phosphorylation of the transcription factor, interferon (IFN) regulatory factor 3 (IRF-3) via TRAF
family member-associated NF-κB activator (TANK)-binding kinase (TBK). Once activated, IRF-3
triggers the expression of type I and III IFN and IFN-stimulated nuclear genes. When constitutively
active, the cGAS–STING pathway promotes inflamm-aging by favoring cellular senescence through
IFN-mediated activation of p53 [102–104]. Senescent cells, while remaining metabolically active,
undergo morphological and functional changes that become manifest with the senescence-associated
secretory phenotype (SASP) [105]. This SASP fingerprint encompasses ILs, chemokines, growth factors,
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secreted proteases, and secreted extracellular matrix components [105]. The release of SASP factors
perturbs the local microenvironment through autocrine and paracrine actions aimed at preventing the
growth of damaged cells while recruiting immune cells and promoting tissue repair [106,107]. On a
different note, insufficient clearance of senescent cells during aging may fuel systemic inflammation
via the excessive production of SASP-related pro-inflammatory cytokines (e.g., IL1β, IL6, IL8) [108].
A specific EV SASP (eSASP) has been described [109]. The analysis of exosomes/EV composition
showed protein changes in senescent cells that were largely distinct from those of non-senescent
matching cells [109]. Moreover, vesicle characterization identified plasma membrane protein signatures
of their originating cells [110,111]. Hence, the analysis of eSASP may offer a unique opportunity to
identify senescence biomarkers with a degree of cell-type specificity or arising from different stressors.
Human Immunodeficiency Virus Infection
Inflammation, overreacting innate immunity, and cluster of differentiation (CD)4+ T cell depletion
are hallmarks of HIV infection [112,113]. HIV infection involves an accelerated aging process and, as
such, it confers considerable risk for major geriatric syndromes [80]. A massive release of DAMPs
resulting from dysfunctional autophagy and pyroptosis, a highly inflammatory form of programmed
cell death, has been proposed as a prominent point of convergence between HIV infection and
inflamm-aging [78].
The infectious cycle of HIV is complex and includes an acute and a chronic stage. An early site
of HIV exposure and infection is the gut-associated lymphatic tissue (GALT), the largest component
of the lymphoid system. The GALT comprises tonsils, Peyer’s patches, lymphoid follicles, and
lymphoid cells disseminated throughout the intestinal epithelium and lamina propria [114]. Upon
HIV infection, GALT undergoes progressive CD4+ T cell depletion, which is due to the apoptosis of
infected cells or their elimination by CD8+ cytotoxic T cells, as well as to the cell death of bystander
uninfected T cells [115–117]. At sites of pyroptotic bystander cell death, the release of cellular content
triggers inflammation and attracts HIV-susceptible CD4+ T cells [112,113]. In turn, inflammation and
overreacting type I IFN responses master the chronic phase of the infection. Such changes have also
been described in patients on antiretroviral therapy, in whom drug toxicity and an inflamm-aging-like
state concur to the pathogenesis of HIV-associated comorbidities [118,119].
Among the mechanisms involved in the complex pathophysiology of HIV, dysfunctional autophagy
seems to play a prominent role [120]. This degradative pathway is crucial for cell-autonomous defense
against HIV variants void of the negative replication factor (Nef) gene [120]. The viral protein Nef
binds to Beclin-1 and blocks the maturation stage of autophagy, thus impeding HIV clearance [121]. A
blockade of autophagy has been described during other viral infections. Indeed, the influenza A virus
M2 protein and the herpes simplex virus 1 protein ICP34.5 have been shown to target Beclin-1 and to
inhibit the late stages of autophagy [122,123].
The finding of Nef-driven inhibition of autophagic maturation might be one of the mechanisms
whereby HIV infection triggers inflamm-aging. Indeed, Nef-induced stalling of autophagy is associated
with the accrual of multivesicular body endosome (MVB)-like organelles [124,125] and the formation of
large vacuoles [126] for all of which a role in the autophagic flux has been hypothesized. In particular,
these structures may represent intermediates of the Nef-imposed block to autophagic maturation that
could assist in virion assembly and maturation or vehiculate its trafficking instead of supporting its
degradation [121]. Even if DNA sensors such as cGAS and various inflammasomes are activated, viral
biomolecules represent only a small fraction of the pool of released molecules. Such an observation
may find an explanation in the pyroptotic nature of the infection. Accordingly, the massive release of
DAMPs, including self-DNA of mitochondrial and genomic origin and DNA-binding proteins such as
chaperones and histones, are in the spotlight for triggering HIV-associated inflammation [82].
Studies reported higher levels of mtDNA in plasma of HIV-1-infected individuals [3,127,128]
and decreased mitochondrial fitness in regulatory CD4+ T cells of immunological non-responders
(i.e., patients not showing satisfactory immune recovery under antiretroviral therapy) [129,130].
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Circulating genomic DNA (gDNA) and mtDNA acquire immunogenic properties and become accessible
to intracellular DNA sensors when bound to chaperones, such as high-mobility group box protein
1, histones, or secreted antimicrobial peptides, as well as when transported into EVs [131]. Hence,
mtDNA extruded within EVs or bound to them as part of the DAMPs system has attracted interest as a
tool for the detection of mitochondrial dysfunction and associated inflamm-aging [7,79].
Although age-related and HIV-associated chronic inflammation is primed by different mechanisms,
the release of mitochondrial DAMPs may be a converging mechanism that could be exploited to
develop therapeutics for both conditions.
4. Mitochondrial Quality Control in Neurodegeneration
4.1. Parkinson’s Disease
PD is a neurodegenerative disease condition with complex pathophysiology that recapitulates
all major hallmarks of aging. As such, PD may be envisioned as a prototypical geroscience
condition [4,129,132]. In this scenario, mitochondrial dysfunction in neurons and neuroinflammation
are considered to be relevant pathogenic mechanisms [133,134]. Although the molecular events linking
these two processes are yet elusive, defective MQC and DAMPs release has been suggested as a
contributing factor [135]. Notably, the deletion of either PINK1 or parkin gene (PARK2) results in a
STING-dependent activation of inflammation as a consequence of disruption of autophagic removal of
damaged mitochondria [135]. Indeed, Parkin, besides its role as a mitophagy mediator, also functions
as a regulator of adaptive immunity by controlling the delivery of mitochondrial antigens to endosomes
where they are loaded on MHC class I molecules [73]. Similarly, the mitophagy regulator RAB7A may
intervene in the regulation of MDV fusion with late endosome for mitochondrial antigen presentation,
as indicated by the accumulation of MDVs in RAB7A knockdown cells [73]. Though, in the absence of
PINK1 or Parkin, mitochondrial antigen presentation in immune cells can still occur via the generation
and trafficking of MDVs [73]. The loss of PINK1/Parkin in PD would, therefore, result in both MQC
disruption and neuroinflammation through MDV-mediated mitochondrial antigen presentation [73].
Recently, mitochondrial DAMPs have been detected within the small EVs purified from the serum
of older adults with PD [6]. The EV molecular profile of PD was also characterized by a specific
inflammatory signature [6]. In particular, older people with PD had higher serum concentrations of
small EVs compared with non-PD controls [6]. The characterization of purified small EVs revealed
that they included exosomes of endosomal origin deriving from the fusion of MVBs with the plasma
membrane [6]. Furthermore, the identification of mitochondrial signatures within small EVs indicated
the presence of circulating MDVs in older adults with PD [6]. Remarkably, lower levels of MDVs
were determined in participants with PD relative to non-PD controls [6]. As previously discussed, the
generation and release of MDVs are regulated through physical and functional interactions between
mitochondria and lysosomes that enable the clearance of damaged mitochondrial constituents [7].
Hence, the increased secretion of small EVs in PD might reflect the cell’s attempt to purge defective
mitochondrial components. In turn, the lower secretion of MDVs may indicate a stalling of the MQC
system in this condition. Indeed, EV cargoes containing damaged mitochondria may also be re-routed
to lysosomes for degradation [25]. Indeed, alterations of lysosomal function were found to be associated
with impaired mitochondrial biogenesis in fibroblasts of a young PD patient with PARK2 mutation [136].
Mutations in the Vps35 gene have also been reported in late-onset PD individuals [137,138]. Notably,
Vps35 protein has been shown to localize at the level of mitochondria and to mediate the generation
and release of MDVs targeted to peroxisomes [139]. The reasons for MDVs delivery to peroxisomes is
still unclear. Though, Vps35 mutations induce extensive mitochondrial fragmentation and impairment
in mitochondrial function leading to neuronal loss in both in vitro and in vivo systems [138]. Moreover,
Parkin has been shown to regulate the retromer complex by modulating the tubular and multivesicular
domain organization of late endosomes that ultimately triggers the generation of intraluminal vesicles
(ILVs) and exosomes [140]. This is enabled by Parkin-mediated ubiquitination of RAB7A at lysine 38,
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which affects its binding to the effector RAB-Interacting Lysosomal Protein (RILP) [140]. Along the
same line, changes in endosomal morphology and membrane dynamics, as well as and retromer and
lysosomal dysfunction, have been found in Parkin-deficient cellular models [141–143]. Accelerated ILV
formation and increased amounts of CD63-positive intraluminal membranes were also observed in
fibroblasts from Parkin-deficient patients, induced pluripotent stem cells (iPS)-derived dopaminergic
neurons, and HEK293 cells knockdown for PARK2 [140].
Finally, the integration of mitochondrial analysis with a multi-marker inflammatory analytical
platform revealed a molecular fingerprint in older adults with PD encompassing MDV markers and
inflammatory biomolecules [6]. The presence of fibroblast growth factor 21 (FGF21) as part of the
molecular signature of PD is particularly relevant. Indeed, FGF21 expression is associated with
dysfunctional MQC in neurons and is induced in the brains of murine models of tauopathy and
prion disease [144]. Hence, FGF21 may represent a “mitokine” and a biomarker for mitochondrial
dysfunction in the brain that warrants investigation [144]. As discussed earlier, these observations
highlight the prospect of scavenging circulating mitochondrial DAMPs, including mtDNA, to obtain
therapeutic gain in PD.
4.2. Alzheimer’s Disease
The accrual of insoluble extracellular amyloid β (Aβ) plaques and intraneuronal Tau tangles,
together with neuroinflammation, are pathological hallmarks of AD [145]. The site of initial Aβ
aggregation is debated; though, it is proposed that excessive intracellular accumulation may eventually
result in neuronal lysis, amyloid leakage, and plaque formation [146]. Indeed, Aβ42, the most
pathogenic Aβ peptide, seems to selectively accumulate in the perikaryon of neurons within lysosomes
or lysosome-derived structures [146]. Alterations of the endolysosomal system are, therefore, believed
to be a major pathogenic pathway in AD. The generation of enlarged and dysfunctional MVBs in the
presence of bulky levels of Aβ42 has been described in AD transgenic neurons [147]. In turn, MVB
impairment induces Aβ accrual in the enlarged endocytic compartment [147]. Furthermore, enhanced
extracellular secretion of amyloid precursor protein (APP) following MVB dysfunction has been found
in AD transgenic mice [147]. The proteolytic cleavage of APP protein by β and γ-secretases induces
aberrant Aβ production [148]. Amyloidogenesis is also influenced by the intracellular trafficking of
APP and the β-site APP-Cleaving-Enzyme (BACE1) and is promoted by the colocalization of APP and
BACE1 in the endosomal compartments [149]. Notably, the activity of the retromer complex reduces
Aβ production by favoring retrograde transport of APP from endosomes to the TGN [150]. Indeed,
impaired retromer complex activity has been involved in AD pathogenesis by promoting higher Aβ
production [150].
A role for RAB7A GTPase in AD has also been shown. A higher expression of RAB7A has been
found in the frontal cortex of transgenic mice with a progressive form of AD [151], while RAB7A
depletion is able to reduce Tau secretion [152]. Hence, RAB7A may contribute to the extracellular
accumulation of pathological Tau species and support the propagation of Tau pathology in AD [152].
This hypothesis is in line with the observations of decreased or increased Tau secretion following the
expression of a dominant-negative (RAB7A T22N) or a constitutively active (RAB7 Q67L) RAB7A
mutant, respectively [152]. The dual role of RAB7A in the regulation of mitophagy and Tau secretion
might, therefore, suggest that the intracellular trafficking mediated by RAB7A may represent a relevant
factor in the pathogenesis of AD.
Defective MQC processes, in particular mitophagy, are considered to be the trait d’union linking
mitochondrial dysfunction and bioenergetic failure in neurons, inflammation, and eventually neuronal
loss [153]. Mitochondrial dysfunction and defective mitophagy have been described in post-mortem
hippocampus neurons of AD patients, in induced pluripotent stem cell-derived human AD neurons,
and in animal models of AD [154]. Strikingly, the restoration of neuronal mitophagy has been shown
to promote the elimination of defective mitochondria, improve mitochondrial bioenergetics, and
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ameliorate cognitive decline in Caenorhabditis elegans models of AD and in the amyloid precursor
protein/presenilin 1 APP/PS1 transgenic mouse AD model [154].
A vicious circle between generation Aβ plaque generation and disruption of neuronal mitophagy
has been hypothesized [153–155]. This pathway might operate through impairment of the mitochondrial
unfolded protein response (UPRmt) machinery, a component of the mitochondrial proteostasis system,
that is believed to link mitochondrial dyshomeostasis to Aβ proteotoxicity [156]. The trafficking of
the activating transcription factor associated with stress (ATFS-1) may play a relevant role in the
process [157]. Under physiologic conditions, ATFS-1 is imported within the mitochondrial matrix and
inhibits the UPRmt [157]. In the setting of mitochondrial dysfunction, instead, ATFS-1 is relocated into
the nucleus where it triggers the expression of genes involved in mitochondrial turnover [157]. A lower
expression of DISC1 has also been detected in postmortem brain regions of AD patients, transgenic
AD mice model, and Aβ-treated cultured cells [158]. Noticeably, DISC1 functions as a mitophagy
receptor containing an LC3-interacting region that promotes mitophagy through its binding to LC3 and
protects synaptic plasticity from Aβ accumulation-induced toxicity, [158]. The phosphorylated-Tau
(p-Tau) protein is another player in the vicious circle between defective mitophagy and mitochondrial
dysfunction [153]. The expression of human wild-type (hTau) and frontotemporal dementia mutant Tau
(hP301L) inhibits Parkin-dependent mitophagy by reducing or blocking the mitochondrial translocation
of Parkin in neuroblastoma cells and Caenorhabditis elegans, respectively [159].
The relevance of defective mitophagy to the pathogenesis of AD is further supported by the
amelioration of cognitive dysfunction and Aβ proteinopathy in APP/PS1 mice following the restoration
of neuronal and microglial mitophagy via supplementation with nicotinamide adenine dinucleotide
(NAD+) precursors, urolithin A, and actinonin [160]. The pharmacological restoration of mitophagy
has also been shown to reduce phosphorylation of Tau at several serine and threonine residues and to
mitigate cytokine-induced inflammation ignited by immune activation of microglia [154].
Signs of neuroinflammation (e.g., inflammatory cytokines in the proximity of Aβ deposits and
neurofibrillary tangles) have been found in AD [161]. In particular, IL1β, IL6, and tumor necrosis
factor alpha (TNF-α) are produced in response to amyloid plaque deposition and are involved in
local inflammation [162]. Sustained production of these cytokines causes neurotoxicity and promotes
the generation of Aβ peptides [162]. Impairments in mitophagy and the ensuing mitochondrial
dysfunction observed in AD may underpin the generation and release of DAMPs with consequent
stimulation of innate immunity by TLR, NLRP, and cGAS–STING systems [93,94]. Similar to PD [6],
mitochondrial DAMPs might be released within MDVs also in AD. Should this pathway be operative,
it may provide a mechanistic explanation for the state of systemic inflammation observed in AD [163].
Furthermore, in-depth characterization of the cargo of circulating MDVs might reveal novel biomarkers
to be used for the identification and monitoring of AD patients.
5. Mitochondrial Quality Control in Cardiovascular Disease
Dysmorphic mitochondria producing high levels of ROS have been found in aged
cardiomyocytes [164] in association with cardiac structural and functional alterations [165]. These
observations laid the ground for the study of mitochondrial dysfunction and inefficient MQC as
mechanisms in heart senescence [5].
The heart is one of the most robust mitophagy organs relying upon this degradative process
for normal functioning [166]. Cardiac autophagy, either selective or unselective, is modulated
by cardiomyocyte energy status via metabolic signaling. Under substrate deficit or oxidative
stress conditions, the drop of intramyocyte ATP activates an energy-sensing pathway involving
5′-AMP-activated protein kinase (AMPK), unc-51-like kinase 1 (ULK1), BCL2, and Beclin-1 [167,168].
The downregulation of the mechanistic target of rapamycin complex 1 (mTORC1), an autophagy
suppressor, further ignites autophagy [169]. To avoid excessive degradation, growth, or cell survival,
stimuli convey anti-autophagic signaling through insulin/insulin-like growth factor 1 (IGF1)/protein
kinase B (AKT1) signaling [170]. In addition, the GTP-binding protein Ras homolog enriched in brain
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(RHEB) represses autophagy primarily via mTORC1 and transcription factors related to lysosomal
biogenesis (i.e., transcription factor EB (TFEB)) [171].
With regard to mitophagy, both PINK-Parkin-dependent and independent pathways have been
described in cardiomyocytes [172]. While canonical PINK-Parkin-dependent mitophagy preserves
mitochondrial and cardiac function in diabetic mice with high-fat diet-induced cardiomyopathy [173],
defects in PINK-Parkin-dependent mitophagy leads to severe cardiac complications in animal models
of Duchenne muscular dystrophy [172]. The expression of negative regulators of cardiomyocyte
mitophagy, such as the mammalian Ste20-like kinase 1 (Mst1), has also been documented in
an experimental model of septic cardiomyopathy [174]. Notably, Mst1 depletion attenuates
lipopolysaccharide (LPS)-induced cardiomyocyte death and preserves cardiac function via promoting
Parkin-dependent mitophagy [174]. Moreover, a role for the adenine nucleotide translocator (ANT)
complex in mitophagy regulation via interaction with TIM23 has been described [175]. This ANT
function is independent of the TIM23-mediated protein translocator and results in the stabilization
of PINK1 at damaged mitochondria for subsequent degradation [175]. The depletion of ANT in the
murine heart causes accrual of dysmorphic mitochondria, cardiomyocyte hypertrophy, and contractile
dysfunction [175]. Notably, patients with homozygous mutations in ANT1 show severe heart failure in
conjunction with cardiac mitochondrial dyshomeostasis [175].
PINK1-Parkin-independent mitophagy, possibly operating via inter-organelle contact sites, has
also been reported in the context of CVD. In particular, the mitochondrial receptor FUNDC1 mediates
the release of Ca2+ from the endoplasmic reticulum (ER) by establishing mitochondrial−ER contacts
through the binding of the ER-inositol 1,4,5-trisphosphate type 2 receptor (IP3R2) [176]. These
inter-organelle contacts are necessary for maintaining fully-functioning mitochondria and preserving
cardiac function [176]. Notably, FUNDC1 expression and FUNDC1-induced mitophagy are repressed
by the negative mitophagy regulator Mst1 [177]. In particular, while Mst1 expression is associated
with cardiac ischemia-reperfusion injury, its depletion preserves mitochondrial and cardiomyocyte
homeostasis [177]. In addition, BNIP3 can trigger mitophagy in cardiomyocytes independent of
cytosolic Ca2+ levels, oxidative stress, and apoptosis signaling [178]. This action is mediated by
phosphorylation of BNIP3 at Ser17 and Ser24, which favors its interaction with LC3, thereby fueling
the mitophagy flux [179]. Of note, the downregulation of BNIP3 via abrogation of c-Jun N-terminal
kinase (JNK) signaling has been found to reverse cardiac remodeling in heart failure [180].
The induction of UPRmt has been shown to mitigate mitochondrial and contractile dysfunction in
cardiomyocytes during pressure overload [181]. Remarkably, the severity of heart failure, as well as the
extent of cardiomyocyte apoptosis and cardiac fibrosis, were found to be attenuated in patients with
aortic valve stenosis with higher RNA expression of UPRmt mediators [181]. A cardioprotective role
has also been hypothesized for RAB7A [182]. Indeed, the stimulation of the mitochondrial aldehyde
dehydrogenase 2 (ALDH2) activity has been shown to upregulate autophagy via RAB7A, thereby
mitigating oxidative damage in the aged heart [183].
Finally, MDV generation has been proposed as a mechanism to dispose of mildly oxidized
mitochondria independent of mitochondrial depolarization, autophagy signaling, or mitochondrial
fission [184]. In cultured H9c2 myoblasts, MDV formation acts as a basal housekeeping process and
occurs more frequently than mitophagy events [184]. MDV generation is upregulated following
exposure to mitochondrial stressors (i.e., antimycin-A and xanthine/xanthine oxidase), while both
MDV production and mitophagy are enhanced in response to extensive mitochondrial damage [184].
Although preliminary, these findings suggest that constitutive MDV generation is necessary for the
maintenance of cardiomyocyte homeostasis under physiologic conditions and also serves as a first-line
defense against mild stressors.
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